A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > BUSINESS
BUSINESS
- Chugai Foresees Tepid Growth for Next 3 Years: New Biz Plan
January 29, 2016
- Kadcyla Development for Gastric Cancer Discontinued: Chugai
January 29, 2016
- Chugai Delivers Record Earnings, but Pegasys Falters on IFN-Free Hep C Therapies
January 29, 2016
- Shionogi, Nissan Chemical Ink Collaboration Pact on Antifungals
January 29, 2016
- Sumitomo Dainippon to Revise 5-Year Business Plan
January 29, 2016
- Ferring Empowers Japan Unit, Local Head Mark Noggle Doubles as CEO
January 29, 2016
- Retooling Generic Business - 1: Daiichi Sankyo Espha Shifting Its Focus to AGs
January 29, 2016
- Shionogi Files Japan NDA for ADHD Drug Licensed from Shire
January 28, 2016
- Mochida Seeks Adenomyosis Indication for Dinagest
January 28, 2016
- 140 Hep C Patients Receive Viekirax in 1st Month
January 27, 2016
- Mochida Set to Achieve 10 Billion Yen Generic Sales in FY2015
January 27, 2016
- MSD Joins with Venture Capital to Offer BD Support for Health-Tech Startups
January 27, 2016
- Mundipharma to Merge Spectrum Unit in March, Become MAH for Zevalin
January 26, 2016
- Kyowa Kirin to Market Sandoz’s Rituximab Biosimilar in Japan
January 26, 2016
- Dispensing Pharmacies Worried about Reversal of Delivery and NHI Prices Following Re-Pricing of Gilead’s “Huge Seller” Hep C Drugs
January 21, 2016
- Maruho, Galderma Team Up to Develop, Market Skin Treatments in Japan
January 19, 2016
- Toa Eiyo to Take Over Astellas’s Marketing Authorization for Cibenol
January 19, 2016
- GSK to Resume Shipment of Hep B Drug Tenozet
January 18, 2016
- Novartis Partners with Meiji Seika Pharma to Promote COPD Drugs
January 18, 2016
- Ethical Drug Sales Jump 15.2% in November: Crecon Report
January 18, 2016
ページ
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…